Navigation Links
KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM)
Date:1/22/2008

Potential NDA Approval for Gestiva(TM) Anticipated in Calendar 2008 Gestiva(TM), is Designated as an Orphan Drug by the FDA for the Prevention

of Preterm Birth in Singleton Pregnancies

ST. LOUIS, Jan. 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that it has entered into a definitive purchase agreement that gives KV full U.S. and worldwide rights to Gestiva(TM) (17-alpha hydroxyprogesterone caproate) upon approval of the pending Gestiva(TM) New Drug Application ("NDA").

The NDA for Gestiva(TM) is currently before the FDA, pending approval for use in the prevention of preterm birth in certain categories of pregnant women. The proposed indication is for to women with a history of at least one spontaneous preterm delivery (i.e., less than 37 weeks), who are pregnant with a single fetus. The FDA issued an "approvable" letter for Gestiva(TM) in October 2006, and a final approval is anticipated in late 2008. The FDA has granted an Orphan Drug Designation for Gestiva(TM).

KV is acquiring Gestiva(TM) from Massachusetts-based Hologic, Inc. for $82 million in cash, $7.5 million of which is payable at closing. The balance is payable upon final FDA approval and the production of launch quantities of Gestiva(TM). KV expects Gestiva(TM) to be additive to KV's earnings per share in the first 12 months following its launch.

"Gestiva(TM) marks an exciting and important extension to Ther-Rx's growing women's health franchise," said Marc S. Hermelin, Chairman of the Board and Chief Executive Officer of KV. "Our commitment to women's health is second-to-none in the industry and we believe the acquisition of Gestiva(TM), following the acquisition of our approved and soon-to-be-launched Evamist(TM)
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
2. Pharmaceutical market fails pregnant women; and more
3. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
4. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
5. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
9. Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes
10. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
11. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... the world’s leading healthcare suppliers will utilize the ... 1WorldSync’s product information network to share product information ... and other trading partners across their global supply ... Auto ID at B. Braun: "B. Braun serves ...
(Date:7/29/2014)... July 29, 2014 Mach7 Technologies, ... announced today the release of an enhanced version ... , Mach7’s Physician & Patient Portal enables ... Patients gain access to a comprehensive view of ... seamlessly consolidates complete patient care records and intelligently ...
(Date:7/29/2014)... Collierville, TN (PRWEB) July 29, 2014 ... to the reimbursement model of all hospitals. Studies show ... tsunami.[1] One simple, easy, low cost tool that ... organizational performance by 20 to 25%. , Their secret? ... to one anther at the end of an operational ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 TMG ... Outsourcing solutions for health plans in the Medicare ... Medicaid markets recently held its annual Client Forum ... Under the conference theme, “Partners in Excellence: Navigating ... executives and operations leaders from TMG Health’s Client ...
(Date:7/29/2014)... Kathleen Doheny HealthDay ... Healthy women at low risk of cardiovascular disease may be ... a short time without harming their hearts, according to a ... Initiative, found that hormone replacement therapy had harmful effects on ... they began the hormone treatments, and much further past menopause. ...
Breaking Medicine News(10 mins):Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 2Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 2Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3
... This release is available in French . ... enable the region to build research capacity and conduct clinical ... HIV/AIDS and Malaria for the conduct of clinical trials) is ... region to conduct high-quality clinical trials. It will be supported ...
... zeros in on root causes of defects on the ... whose assembly manufacturing quality systems are used by companies ... as they occur, has been named a preferred supplier ... cementing its position in a key growth market for ...
... MUNICH, Feb. 25 Smith & Nephew,s,Orthopaedics ... which,BrainLAB will become the exclusive vendor for developing ... high performance,hip and knee implants. , ... will begin work integrating,the Smith & Nephew portfolio ...
... of Texas M. D. Anderson Cancer Center ... Knife (R) Perfexion(TM), an advanced radiosurgery ... lesions in the head in a single session, ... )"Leksell Gamma Knife Perfexion suits our clinical needs," ...
... Mass. and GAITHERSBURG, Md., Feb. 25 ... a systems biology company focused on identifying ... develop novel therapeutics, molecular diagnostics and patient-specific ... a partnership agreement with Gene Logic, an ...
... Aton Pharma, Inc., a,diversified specialty pharmaceutical company, ... to the TIMOPTIC(R) product line from Merck & ... receptor,blocking agent indicated for the treatment of elevated ... glaucoma. As many as 2.25,million Americans suffer from ...
Cached Medicine News:Health News:CANTAM first African Network of Excellence for clinical trials 2Health News:Sciemetric makes the grade with major medical device manufacturer 2Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 2Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 3Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 4Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 2Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 4Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 2Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 3
(Date:7/29/2014)... 29, 2014  Drug development for hepatitis C ... rates and the intense need for curative therapy ... is underway as the market moves away from ... easily-tolerated, interferon-free oral therapies. Logo ... mega blockbuster Sovaldi is the first of these ...
(Date:7/29/2014)... WHEAT RIDGE, Colo. , July 29, 2014 ... technology company focused on developing a proprietary electromagnetic ... announced it entered into an agreement under which ... -based Continuation Investments Limited (COT) in an all-stock ... the Company will initially trade on the Australian ...
(Date:7/29/2014)... , July 29, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release second quarter 2014 financial results on Tuesday, ... The Company,s management will hold a conference call ... which is 8:00 p.m., Beijing Time on August 6, ...
Breaking Medicine Technology:A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3
... 2011 /PRNewswire-iReach/ -- URINOZINC® Plus with Beta-Sitosterol, ... is now available for purchase at select Walmart stores. ... is the only dietary supplement with a US Patent ... Over 2 million bottles have been sold. ...
... CardioMEMS, Inc ., an Atlanta-based medical device company that ... and communication technology for the human body, today announced ... , has been honored with a Ernst & Young ... category for the Alabama/Georgia/Tennessee region.  According to Ernst & ...
Cached Medicine Technology:Walmart Stores Now Offer URINOZINC® Plus With Beta-Sitosterol 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Named Ernst & Young Entrepreneur of the Year® 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Named Ernst & Young Entrepreneur of the Year® 3
... with powder-coated steel legs. Height ... in hundreds of sizes and ... light fixtures and ionizing equipment. ... custom building to meet special ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... BioSafe room is configured specifically for ... chemical analysis. Panels are precision-joined to ... to wipe down and disinfect. One-inch ... panel design creates strong, rigid surface ...
... The ideal modular cleanroom for ... applications that require cleanliness (to Class ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ...
Medicine Products: